GNE Myopathy Clinical Trial
Official title:
International GNE Myopathy Patient Registry (GNE001)
GNE myopathy, an ultra-rare disease, is a severe progressive myopathy that typically presents
in early adulthood as weakness in the distal muscles of the lower extremities and progresses
proximally, leading to a loss of muscle strength and function, and ultimately a
wheelchair-bound state. The rate of progression is gradual and variable over the course of
10-20 years or longer.
There is a need to understand the world wide epidemiology of this ultra-rare condition,
better understand a long-term disease course and the progression of disease-specific
features, support translational research by evaluating burden illness and support clinical
research recruitment. Therefore, the study will longitudinally collect information via an
online patient registry platform.
GNE myopathy is an ultra- rare condition. Most of the knowledge is coming from case reports
or small cohort observations. There is a need to more precisely understand the long-term
disease course and the progression of disease-specific features of GNE myopathy, and in turn
characterise the overall burden of this illness. Also, to better understand the disease,
describe it variability, genotype-phenotype correlation, quality of life, epidemiology,
health-economics aspects and need for assistive walking devices. Collected data needs to be
harmonised to be compatible collaborative work with Remudy (Japanese patient registry). This
collaborative effort will enable the analysis of the largest GNE myopathy data set in the
world. To this end, this study will collect patient information longitudinally. Upon
patient's agreement, the registry curator can contact nominated clinicians to request
additional data or data validation.
Study Objectives
The objectives of the study are to:
- Longitudinally characterize disease-specific features of GNE myopathy
- Characterize the burden of illness and quality of life in patients with GNE myopathy
- Support recruitment in research activities
- Inform registry participants via newsletters about scientific developments in the GNE
myopathy field
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01417533 -
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases
|
||
Completed |
NCT01634750 -
Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
|
Phase 1 | |
Completed |
NCT01517880 -
A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy
|
Phase 2 | |
Completed |
NCT02377921 -
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
|
Phase 3 | |
Terminated |
NCT02736188 -
Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
|
Phase 3 | |
Completed |
NCT01830972 -
An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy
|
Phase 2 | |
Completed |
NCT04671472 -
Efficacy Confirmation Study of NPC-09
|
Phase 3 | |
Completed |
NCT02346461 -
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
|
Phase 2 | |
Active, not recruiting |
NCT04231266 -
Multi-Center Study of ManNAc for GNE Myopathy
|
Phase 2 | |
Completed |
NCT01784679 -
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
|
||
Terminated |
NCT02731690 -
A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment
|
Phase 2 |